Riskpilot← Back to searchSign inGet full accessEmbryoTrans Biotech ApS
APSDissolvedCVR 36701676Sommervænget 2Retail sale of medical and orthopaedic goods · NACE 4774Est. 20151 employees
Revenue 2020
DKK 520K
-61% vs 2019
EBITDA margin
-1.2%
-114% vs 2019
Equity ratio
67.7%
Financial strength
Net profit 2020
DKK -10K
-145% vs 2019
| Revenue | DKK 520K | -61% |
| EBITDA | DKK -6K | -114% |
| Net profit | DKK -10K | -145% |
| Total assets | DKK 358K | -28% |
| Equity | DKK 242K | -4% |
| Employees | 1 | — |
Legal name
EmbryoTrans Biotech ApS
CVR number
36701676
Legal form
Anpartsselskab
NACE code
4774 · Retail sale of medical and orthopaedic goods
Founded
22. marts 2015
Share capital
DKK 50.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2020-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør eller af den samlede bestyrelse.
Address
Sommervænget 2
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 1.134 | 1.767 | 1.838 | 1.136 | 1.320 | 520 |
| Staff expenses | -772 | -1.585 | -1.597 | -1.144 | -1.277 | -526 |
| EBITDA | 362 | 182 | 242 | -8 | 43 | -6 |
| Depreciation & amort. | -3 | -4 | -4 | -4 | -4 | -1 |
| EBIT | 359 | 178 | 237 | -12 | 38 | -7 |
| Net financials | -1 | -3 | -5 | -2 | -4 | -0 |
| Profit before tax | 358 | 175 | 232 | -15 | 35 | -8 |
| Tax | 85 | 43 | 60 | 3 | 11 | 3 |
| Net profit | 273 | 132 | 172 | -18 | 23 | -10 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Total assets | 898 | 838 | 1.270 | 745 | 498 | 358 |
| Equity | 323 | 455 | 377 | 260 | 253 | 242 |
| Long-term debt | 0 | 0 | 0 | 0 | 6 | 0 |
| Short-term debt | 573 | 379 | 893 | 486 | 239 | 116 |
| Total debt | 573 | 379 | 893 | 486 | 245 | 116 |
EBITDA margin
-1.2%
This company
15.8%
Market median
-108% vs market
20152020
Equity ratio
67.7%
This company
38.2%
Market median
+77% vs market
20152020
Return on equity
-4.3%
This company
18.4%
Market median
-123% vs market
20152020
Net profit margin
-2.0%
This company
8.1%
Market median
-125% vs market
20152020
Asset turnover
1.45×
This company
1.12×
Market median
+29% vs market
20152020
Debt / equity
0.48×
This company
0.62×
Market median
+23% vs market
20152020
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-03-23 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LB Management | Management | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Board of Directors | 2015 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
STROEBECH CONSULT HOLDING ApS | Company | 66.7% | 66.7% | 2015 |
| Individual | 10.0% | 10.0% | 2015 | |
TRINE HASTRUP & BJARNE JØRNSGÅRD HOLDING ApS | Company | 33.3% | 33.3% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of EmbryoTrans Biotech ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lotte Bjørg Strøbech | Management | 0 companies |
| Trine Hastrup | Chairman | 0 companies |
| Bjarne Jørnsgård | Board of Directors | 0 companies |
| Ulrik Bangsbo Hansen | Chairman | 0 companies |